Open AccessNovel antibody–drug conjugates: current and future roles in gynecologic oncology
Author(s) -
Joan TymonRosario,
Burak Zeybek,
Alessandro D. Santin
Publication year - 2020
Publication title -
current opinion in obstetrics and gynecology/current opinion in obstetrics and gynecology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 73
eISSN - 1080-8256
pISSN - 1040-872X
DOI - 10.1097/gco.0000000000000642
Subject(s) - medicine , antigen , antibody drug conjugate , bystander effect , antibody , trastuzumab emtansine , ovarian cancer , cancer research , trastuzumab , gynecologic oncology , oncology , cytotoxic t cell , cancer , pharmacology , immunology , monoclonal antibody , breast cancer , biology , in vitro , biochemistry
Antibody-drug conjugates (ADCs) represent a new class of drugs that combine a surface receptor-targeting antibody linked to a cytotoxic molecule. This review summarizes the current literature demonstrating their tremendous promise as therapeutic agents in the treatment of aggressive gynecologic malignancies.